Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Clinical Trials

Clinical Trials at The Methodist Hospital Research Institute

Search results...

Immune System Diseases

Active and enrolling clinical trials for Immune System Diseases are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Lymphoma

C14012: Alisertib or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexat...(read more)

GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Dotting , Andrea
Phone: 713-441-8029
Summary:This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory...(read more)

MLN8237 in Relapsed or Refractory Aggressive B-Cell Lymphoma - C14011
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Woodard, Karen
Phone: 713-441-4332
Summary:This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transf...(read more)

OMB113676 Head to Head Trial of Ofatumumab versus Rituximab
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This is a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-se...(read more)